From BioHealth Investor
Biotechnology
HALOZYME THERAPEUTIC [HTI] +9.87%
XTL BIOPHARMACEUTICA [XTLB] +9.02%
HEMOBIOTECH INC [HMBT.OB] +8.50%
NOVACEA, INC. [NOVC] +7.46%
LEV PHARMACEUTICALS [LEVP.OB] +6.51%
Diagnostic Substances
RG GLBL LIFESTYLS [RGBL.OB] +14.61%
AVALON PHARMACEUTIC [AVRX] +12.34%
ICAGEN, INC. [ICGN] +6.15%
PRESSURE BIOSCIENC [PBIO] +4.68%
HEALTHCARE TECH LTD [HCTL] +3.75%
Drug Delivery
SKYEPHARMA PLC [SKYE] +2.60%
NOVADEL PHARMA INC [NVD] +2.31%
HOSPIRA INC [HSP] +2.17%
COLUMBIA LABS INC [CBRX] +1.08%
GENEREX BIOTECH CORP [GNBT] +0.57%
Drug Manufacturers
TAPESTRY PHARMA INC [TPPH] +11.26%
ACCESS PHARMACEUTICL [ACCP.OB] +5.77%
ARQULE INC [ARQL] +4.44%
TELIK INC [TELK] +3.08%
NEUROCHEM INC [NRMX] +2.87%
Medical Appliances & Equipment
ALPHA INNOTECH [APNO.OB] +13.64%
EMERGENT GROUP INC [EMGP.OB] +7.25%
ENDOCARE INC [ENDO.OB] +7.00%
CAMBRIDGE HEART INC [CAMH.OB] +5.33%
CHAD THERAPEUTICS [CTU] +4.78%
Medical Instruments & Supplies
MILESTONE SCIENTIFIC [MLSS.OB] +12.90%
NUCRYST PHARMACEUTIC [NCST] +6.25%
IVAX DIAGNOSTICS INC [IVD] +5.93%
CANTEL MEDICAL CORP [CMN] +3.82%
ANGEION CORP [ANGN] +3.81%
Medical Laboratories & Research
MEDASORB TECHNOLOGS [MSBT.OB] +4.00%
SPHERIX INC [SPEX] +0.50%
LABORATORY CORP NEW [LH] +0.22%
http://www.biohealthinvestor.com/
Essential Tips for Investing: Sponsored
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
